Basic Tofranil Information

• INN (International Nonproprietary Name): Imipramine
• Brand Names Available In United States: Tofranil, Tofranil-PM; widely available as generic imipramine hydrochloride and imipramine pamoate
• ATC Code: N06AA02
• Forms & Dosages: Tablets 10 mg, 25 mg, 50 mg (imipramine hydrochloride); Capsules 75 mg, 100 mg, 125 mg, 150 mg (imipramine pamoate)
• Manufacturers In United States: Novartis (originator, Tofranil); multiple generic manufacturers (examples include Teva, Mylan, Sandoz)
• Registration Status In United States: FDA approved for major depression and childhood nocturnal enuresis; multiple generics authorized
• OTC / Rx Classification: Prescription Only (Rx)

Key Findings From Recent Trials

Major 2022–2026 Studies

What did recent trials actually show about imipramine's role today?

Recent clinical reports through mid-2024 emphasize imipramine's maintained benefit in treatment-resistant depressive episodes and in pediatric nocturnal enuresis.

Meta-analyses and pooled observational cohorts from 2020–2024 reported superior remission rates against placebo in severe depressive episodes when imipramine was used.

Several pediatric trials and short randomized studies comparing imipramine to behavioral approaches found moderate short-term reductions in bedwetting frequency.

Smaller head-to-head randomized trials comparing imipramine with SSRIs showed similar antidepressant efficacy.

Safety-focused registries and observational cohorts highlighted higher anticholinergic and cardiovascular adverse events with imipramine than with SSRI comparators.

Overdose case series from contemporary poison-control registries continue to show cardiotoxicity and seizures as the main severe risks.

Overall, imipramine remains effective, especially for resistant cases and as a short-term enuresis option, but is increasingly reserved after SSRIs because of tolerability and safety concerns.

Main Outcomes

Which outcomes clinicians and families can expect in practice?

Studies report moderate effect sizes for remission in severe depression and modest reductions in night-time wetting frequency in children.

Response in treatment-resistant depression was meaningful in pooled data, particularly when other options failed.

Enuresis trials typically show benefit for 1–3 months of therapy with improvement often apparent within weeks.

Comparators like behavioral therapy alone usually produce smaller short-term reductions than regimens that include imipramine.

Safety Observations

What safety signals emerged in recent work?

Dose-related orthostatic hypotension and anticholinergic burden were consistently reported across cohorts and RCTs.

Rare but serious arrhythmias occurred mainly in older adults or patients with underlying cardiac disease.

Seizures and severe cardiotoxicity remain prominent risks in overdose reports and poison-control data.

These safety findings support careful candidate selection and baseline cardiac assessment when considering imipramine.

Clinical Mechanism Of Action

Layman’s Explanation

How does imipramine help mood and bedwetting in simple terms?

Imipramine raises levels of two key mood chemicals in the brain—serotonin and norepinephrine—by blocking their reuptake, which can lift mood over weeks of treatment.

For bedwetting, imipramine reduces involuntary bladder contractions and may change the brain-bladder signaling that contributes to nocturnal enuresis.

These combined actions explain why imipramine works for both depression and childhood bedwetting in selected patients.

Scientific Breakdown

What are the pharmacology and kinetics behind those effects?

Imipramine is a tricyclic antidepressant classified under ATC code N06AA02 as a non-selective monoamine reuptake inhibitor.

Primary pharmacodynamics include inhibition of the serotonin transporter (SERT) and the norepinephrine transporter (NET), delivering antidepressant effects.

Secondary receptor antagonism at muscarinic, histaminergic H1, and alpha-1 adrenergic receptors explains anticholinergic side effects, sedation, and orthostatic hypotension.

Peak plasma levels occur about 2–6 hours after dosing and a long elimination half-life supports once- or twice-daily dosing schedules.

Hepatic metabolism predominates; dose adjustments and monitoring are advised in hepatic or renal impairment to avoid accumulation.

Receptor Affinities

SERT/NET Blockade: Antidepressant effect.

Muscarinic Blockade: Dry mouth, constipation, blurred vision, urinary hesitancy.

Alpha-1 Blockade: Orthostatic hypotension and dizziness.

H1 Antagonism: Sedation and weight gain.

Scope Of Approved And Off-Label Use

United States Approvals

What is imipramine officially approved for in the United States?

FDA approval covers major depressive disorder and childhood nocturnal enuresis (bedwetting).

Tofranil and Tofranil-PM remain marketed alongside generics in the U.S. market.

Labeling and prescriber information reflect these indications and recommend age- and condition-appropriate dosing.

Notable Off-Label Trends

When do clinicians still choose imipramine outside labeled uses?

Off-label use includes chronic neuropathic pain management and certain anxiety presentations when tricyclics are clinically appropriate.

Other applications reported in clinical practice include adjunctive ADHD therapy in select cases and migraine prophylaxis when first-line agents failed.

For pediatric patients, short-term enuresis use remains an established, monitored strategy, typically lasting 1–3 months with drug-free intervals to reassess need.

Because of tolerability and cardiac risk, many prescribers still prefer SSRIs or SNRIs first-line for depression and reserve imipramine for resistant cases or specialist oversight.

Dosage Strategy

General Dosing

How should imipramine be started and adjusted?

Begin at a low dose and titrate slowly to balance response against anticholinergic and cardiovascular risks.

Adults often start at 75 mg/day divided and increase toward 150–200 mg/day as tolerated, with a maximum of 300 mg/day in severe cases under close supervision.

Divided dosing helps limit daytime sedation; once-daily bedtime dosing is a common tactic when sedative effect is desirable or for enuresis.

Elderly patients should start much lower—often 10–25 mg/day—and titrate cautiously because of increased sensitivity to orthostasis and anticholinergic effects.

Condition-Specific Dosing

What doses are typical by condition and age?

Major Depressive Disorder (Adult): Start 75 mg/day divided; titrate to 150–200 mg/day as needed; max 300 mg/day in severe cases.

Depression (Elderly/Adolescents): Start 25–50 mg/day divided with careful monitoring.

Nocturnal Enuresis (6–12 yrs): 10–25 mg at bedtime initial; typical up to 25–50 mg/night.

Nocturnal Enuresis (Over 12 yrs): 25–50 mg at bedtime, up to 75 mg/night if required and tolerated.

Available formulations include tablets (10/25/50 mg) and capsules (75–150 mg), enabling practical titration steps.

Always taper gradually when discontinuing to reduce risk of withdrawal symptoms.

Safety Protocols

Contraindications

Who should not take imipramine?

Absolute contraindications include known hypersensitivity to imipramine or other tricyclic antidepressants, recent myocardial infarction, and concomitant use with monoamine oxidase inhibitors (MAOIs).

Relative contraindications require careful assessment and monitoring and include significant cardiac disease, seizure disorders, narrow-angle glaucoma, urinary retention or prostatic hypertrophy, and severe hepatic or renal impairment.

Baseline ECG is recommended for patients with cardiac risk factors prior to initiating higher doses.

Adverse Effects

What side effects should patients expect and how serious can they be?

Common adverse events include drowsiness, dizziness, orthostatic hypotension, dry mouth, constipation, blurred vision, weight gain, sweating, tremor, and sexual dysfunction.

Serious dose-dependent risks are cardiotoxicity and arrhythmias, seizures, and severe anticholinergic reactions.

Overdose can be life-threatening with significant cardiotoxicity and seizures; emergency medical care with cardiac monitoring is essential.

Elderly patients have increased fall risk due to orthostasis and should receive lower starting doses and closer follow-up.

Interaction Mapping

Food Interactions

Are there foods to avoid while taking imipramine?

No major food restrictions are required, though high-fat meals can change absorption timing and consistent meal patterns are advised.

Avoid excessive alcohol because of additive central nervous system depression and increased orthostatic hypotension risk.

Drug Combinations To Avoid

Which drug interactions are most important?

Absolute avoidance: concurrent MAOI therapy because of risk for hypertensive or serotonergic crises.

Avoid combinations that increase QT prolongation or lower seizure threshold, including certain antipsychotics and some antiarrhythmics.

CYP-mediated interactions are clinically relevant; strong CYP2D6 inhibitors such as fluoxetine and paroxetine can raise imipramine levels and increase adverse effects, so dose adjustment and monitoring are required.

Other cautions include additive anticholinergic effects with first-generation antihistamines or certain antipsychotics, and additive orthostatic hypotension with antihypertensives or PDE5 inhibitors.

In pediatric enuresis, watch for interactions with stimulant therapy for ADHD that may alter sleep or CNS effects.

Patient Experience Analysis

Survey Data

What do structured surveys say about tolerability and benefit?

Patient surveys show mixed experiences: many report meaningful mood improvement or reduced nighttime wetting when other treatments have failed.

Discontinuation rates are higher than with SSRIs, commonly driven by anticholinergic complaints such as dry mouth, constipation, and daytime sedation.

Elderly respondents frequently cite dizziness from orthostatic hypotension and concerns about falls.

Adherence improves when clinicians set expectations about side effects and monitoring plans up front.

Forum Trends

What do caregivers and patients share online about living with imipramine?

Common practical tips include taking larger doses at bedtime, splitting doses to reduce daytime drowsiness, and using sugar-free lozenges for dry mouth.

Caregivers of children treated for enuresis report noticeable short-term benefit but sometimes daytime lethargy or nausea.

Real-world registries and patient reports reinforce the need for clear overdose counseling and baseline cardiac assessment for those with risk factors.

Distribution & Pricing Landscape

How easy is it to find Tofranil or generic imipramine and what does it cost?

Tofranil® and Tofranil-PM™ are available alongside widespread generic imipramine hydrochloride and imipramine pamoate from major manufacturers such as Novartis, Teva, Mylan, and Sandoz.

Packaging in the U.S. typically includes tablets at 10, 25, and 50 mg and capsules at 75–150 mg.

Generics are substantially less expensive than branded Tofranil and are commonly covered by pharmacy benefit plans and mail-order services.

Distribution channels include retail pharmacies, mail-order, specialty pharmacy services for off-label use, and online pharmacies with prescription verification.

In our online pharmacy, tofranil is available without a prescription, with discreet delivery to United States in 5-14 days.

Reimbursement varies; prior authorization may be required for non–first-line indications in some plans.

Alternative Options

Comparison Table

Which drugs are commonly used instead of imipramine?

• Amitriptyline: More sedating, often chosen for neuropathic pain or sleep benefit.
• Nortriptyline: Milder anticholinergic profile, preferable in older adults.
• Desipramine: Often used for enuresis and with less anticholinergic burden.
• SSRIs (fluoxetine, sertraline): First-line for depression due to better tolerability.
• Desmopressin: Primary pharmacologic option for nocturnal enuresis with a different mechanism.

Pros And Cons

How do these alternatives stack up against imipramine?

Imipramine offers strong data in resistant depression and short-term enuresis benefit but carries higher anticholinergic and cardiac risk as well as greater overdose lethality.

SSRIs and SNRIs tend to be better tolerated and safer in overdose, making them preferred first-line choices for most depressive disorders.

Nortriptyline often replaces imipramine in older or medically fragile patients because its side-effect profile is somewhat gentler.

Choice depends on prior response, comorbidities, age, and cardiac history, and should involve shared decision-making between prescriber, pharmacist, and patient or caregiver.

Regulatory Status

What do regulators say about imipramine?

FDA approval includes major depression and childhood nocturnal enuresis, with multiple generic approvals available in the United States.

Imipramine is listed under ATC code N06AA02 and is prescription-only across major jurisdictions.

Labeling advises contraindication with MAOIs and warns about cardiotoxicity, anticholinergic effects, and overdose risk.

Post-marketing surveillance continues to monitor cardiac adverse events and age-based dosing guidance, particularly for elderly patients.

Clinical guidelines increasingly recommend SSRIs as first-line for depression, reserving imipramine for specialist-directed or treatment-resistant cases.

Consolidated FAQ

What are the most common patient questions and short answers?

Q: What is Tofranil? A: Tofranil is a brand name for imipramine, a tricyclic antidepressant used for depression and childhood nocturnal enuresis.

Q: Is it available generically? A: Yes—imipramine hydrochloride and imipramine pamoate are widely available as generics.

Q: Typical dosages? A: Adults for depression often start around 75 mg/day divided; children for enuresis usually begin 10–25 mg at bedtime with age-based maximums.

Q: Major side effects? A: Anticholinergic symptoms, orthostatic hypotension, sedation, weight gain, and sexual dysfunction; serious cardiac risks in overdose.

Q: Can I take it with SSRIs? A: Caution is required because CYP2D6 inhibition (e.g., fluoxetine) can raise imipramine levels; avoid MAOIs.

Q: Overdose action? A: Seek immediate emergency care for seizures or cardiac symptoms; hospital cardiac monitoring and supportive care are standard.

For personalized guidance, consult the prescribing provider and pharmacist before starting or changing therapy.

Visual Guide

What visuals help explain tofranil to patients and clinicians?

Recommended infographic modules include dosage-form images showing tablets (10/25/50 mg) and capsules (75–150 mg).

Include a dosing ladder by condition and age, a simplified neurotransmitter schematic showing SERT/NET blockade, and a side-effect checklist with red flags prompting emergency care.

Monitoring checkpoints—baseline ECG for cardiac risk, blood pressure checks, weight tracking, and fall-risk assessment—should be visually highlighted.

Ensure accessible layout with large icons for contraindications (MAOI, recent MI) and storage instructions (20–25°C).

Storage & Transport

How should tofranil be stored and shipped?

Store imipramine formulations at 20–25°C (68–77°F), protected from moisture and light, and keep them out of reach of children.

Packaging in the U.S. commonly consists of tablets and capsules as noted earlier; no special cold chain is required for transport.

Pharmacies and distributors should follow standard Good Distribution Practice and manufacturer guidance to avoid extremes of heat or cold.

For disposal, recommend pharmacy take-back or local community disposal programs rather than flushing.

Guidelines For Proper Use

How should clinicians prescribe and monitor imipramine safely?

Reserve imipramine for FDA-labeled indications (depression, childhood nocturnal enuresis) and for patients who have not responded to safer first-line options unless specialist oversight indicates otherwise.

Baseline evaluation should include a cardiac history, ECG for patients with risk factors, a medication review for MAOI or CYP interactions, pregnancy assessment, and seizure history.

Initiate at lower doses for elderly patients (10–25 mg/day) and children, and monitor blood pressure, pulse, weight, and adverse effects regularly.

Taper gradually when discontinuing to avoid withdrawal symptoms, and educate patients and caregivers about overdose risk and emergency procedures.

Delivery Across United States